Ovid Therapeutics Inc. Files 2023 Annual Report on Form 10-K

Ticker: OVID · Form: 10-K · Filed: 2024-03-08T00:00:00.000Z

Sentiment: neutral

Topics: 10-K, Ovid Therapeutics, Annual Report, Biopharmaceutical, Financials

TL;DR

<b>Ovid Therapeutics Inc. has filed its annual 10-K report for the fiscal year ending December 31, 2023.</b>

AI Summary

Ovid Therapeutics Inc. (OVID) filed a Annual Report (10-K) with the SEC on March 8, 2024. Ovid Therapeutics Inc. filed its 2023 Form 10-K on March 8, 2024. The filing covers the fiscal year ending December 31, 2023. Key entities mentioned include Gensaic Inc., Graviton Bioscience Corporation, Marinus Therapeutics Inc., and Ligand Pharmaceuticals Incorporated. The company's business address is 441 Ninth Avenue, 14th Floor, New York, NY 10001. The SIC code for Ovid Therapeutics Inc. is 2834 (Pharmaceutical Preparations).

Why It Matters

For investors and stakeholders tracking Ovid Therapeutics Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Ovid Therapeutics' financial performance, business operations, and risk factors for the fiscal year 2023, which is crucial for investors to assess the company's current standing and future prospects. The detailed information within the filing, including financial statements and disclosures about partnerships and agreements, allows stakeholders to understand the company's strategic direction and potential growth drivers in the pharmaceutical sector.

Risk Assessment

Risk Level: medium — Ovid Therapeutics Inc. shows moderate risk based on this filing. The company's financial health and ability to fund its operations and research and development activities are subject to its ability to secure additional financing, as indicated by the nature of its business as a biopharmaceutical company.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand Ovid Therapeutics' financial position and future funding needs.

Key Numbers

Key Players & Entities

FAQ

When did Ovid Therapeutics Inc. file this 10-K?

Ovid Therapeutics Inc. filed this Annual Report (10-K) with the SEC on March 8, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by Ovid Therapeutics Inc. (OVID).

Where can I read the original 10-K filing from Ovid Therapeutics Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Ovid Therapeutics Inc..

What are the key takeaways from Ovid Therapeutics Inc.'s 10-K?

Ovid Therapeutics Inc. filed this 10-K on March 8, 2024. Key takeaways: Ovid Therapeutics Inc. filed its 2023 Form 10-K on March 8, 2024.. The filing covers the fiscal year ending December 31, 2023.. Key entities mentioned include Gensaic Inc., Graviton Bioscience Corporation, Marinus Therapeutics Inc., and Ligand Pharmaceuticals Incorporated..

Is Ovid Therapeutics Inc. a risky investment based on this filing?

Based on this 10-K, Ovid Therapeutics Inc. presents a moderate-risk profile. The company's financial health and ability to fund its operations and research and development activities are subject to its ability to secure additional financing, as indicated by the nature of its business as a biopharmaceutical company.

What should investors do after reading Ovid Therapeutics Inc.'s 10-K?

Investors should review the detailed financial statements and risk factors in the 10-K to understand Ovid Therapeutics' financial position and future funding needs. The overall sentiment from this filing is neutral.

How does Ovid Therapeutics Inc. compare to its industry peers?

Ovid Therapeutics Inc. operates in the pharmaceutical preparations industry, focusing on the development of novel therapies.

Are there regulatory concerns for Ovid Therapeutics Inc.?

The company is subject to standard SEC regulations for public companies, including the requirement to file annual reports (10-K) detailing its financial and operational status.

Risk Factors

Industry Context

Ovid Therapeutics Inc. operates in the pharmaceutical preparations industry, focusing on the development of novel therapies.

Regulatory Implications

The company is subject to standard SEC regulations for public companies, including the requirement to file annual reports (10-K) detailing its financial and operational status.

What Investors Should Do

  1. Review the full 10-K filing for detailed financial statements and disclosures.
  2. Analyze the risk factors section to understand potential challenges and uncertainties.
  3. Research the mentioned entities (Gensaic Inc., Marinus Therapeutics Inc., etc.) for potential strategic relationships or competitive landscape insights.

Key Dates

Year-Over-Year Comparison

This is the initial filing of the 2023 Form 10-K, providing the latest annual financial and operational data for Ovid Therapeutics Inc.

Filing Stats: 4,298 words · 17 min read · ~14 pages · Grade level 15.8 · Accepted 2024-03-08 08:24:19

Key Financial Figures

Filing Documents

Business

Business 3 Item 1A .

Risk Factors

Risk Factors 25 Item 1B. Unresolved Staff Comments 60 Item 1C. C ybersecurity 60 Item 2.

Properties

Properties 61 Item 3.

Legal Proceedings

Legal Proceedings 61 Item 4. Mine Safety Disclosures 61 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 62 Item 6. [Reserved] 63 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 63 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 70 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 71 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 71 Item 9A.

Controls and Procedures

Controls and Procedures 71 Item 9B. Other Information 71 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 71 PART III Item 10. Directors, Executive Officers and Corporate Governance 72 Item 11.

Executive Compensation

Executive Compensation 72 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 72 Item 13. Certain Relationships and Related Transactions, and Director Independence 72 Item 14. Principal Accountant Fees and Services 72 PART IV Item 15. Exhibit and Financial Statement Schedules 73 Item 16. Form 10-K Summary 76 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical fact are "forward-looking statements" for purposes of this Annual Report on Form 10-K. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," continue," "could," "design," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "positioned," "potential," "predict," "project," "should," "target," "will," "would" or the negative or plural of those terms, and similar expressions.

Forward-looking statements include, but are not limited to, statements about

Forward-looking statements include, but are not limited to, statements about: our ability to identify additional novel compounds with significant commercial potential to acquire or in-license; our ability to successfully acquire or in-license additional drug candidates on reasonable terms; our estimates regarding expenses, future revenue, including any royalty or milestone payments, capital requirements and needs for additional financing; our ability to obtain regulatory approval of our current and future drug candidates; our expectations regarding the timing of clinical trials and potential regulatory filings; our expectations regarding the potential market size and the rate and degree of market acceptance of such drug candidates; our ability to fund our working capital requirements; the implementation of our business model and strategic plans for our business and drug candidates; developments or disputes concerning our intellectual property or other proprietary rights; our ability to maintain and establish collaborations or obtain additional funding; our expectations regarding government and third-party payor coverage and reimbursement; our ability to compete in the markets we serve; the impact of government laws and regulations; developments relating to our competitors and our industry; the impact of geopolitical tensions, including war or the perception that hostilities may be imminent, adverse global economic conditions, terrorism, natural disasters or public health crises on our operations, research and development and clinical trials and potential disruption in the operations and business of third parties and collaborators with whom we conduct business; and the factors that may impact our financial results. Factors that may cause actual results to differ materially from current expectations include, among other things, those set forth in Part I, Item 1A, "Risk Factors," herein and for the reasons described elsewhere in this Annual Report on F

BUSINESS

Item 1. BUSINESS Overview Ovid is a biopharmaceutical company that is dedicated to meaningfully improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. We believe that addressing these disorders represents a substantial scientific, medical and commercial opportunity. Over the last decade, scientific understanding of the underlying biology of neuronal hyperexcitability and the related pathophysiology of epilepsy and many neurological disorders has improved. This understanding of disease, coupled with advances in preclinical research tools, is improving the predictive potential of translational research, and thereby, may increase the probability of successful clinical development of anti-seizure medicines ("ASMs"). Emerging science also indicates that addressing the underlying causes of hyperexcitability may have therapeutic applications in broad neurological disease well beyond epilepsy. The large global epilepsy market opportunity reflects significant unmet medical need and economic potential. Epilepsy therapeutics today represent an approximately $8 billion market globally. Evidence supporting the opportunity includes the number of recent acquisitions of epilepsy assets and companies, several of which have been acquired for values greater than $1.0 billion. The unmet need of people affected by seizures remains significant. Approximately three million Americans live with epilepsies today and approximately 50 million people suffer from epilepsy worldwide. We have proven capabilities and expertise in the successful clinical development of ASMs. We have applied our knowledge to build a differentiated pipeline of medicines with potential first-in-class or best-in-class drug mechanisms of action ("MoA") to treat epilepsies and brain disorders with seizure symptoms. Our pipeline has produced three programs with potential first-in-class MoAs, and one program with a potential best-in-class MoA. Currently, three of these p

View on Read The Filing